IL-23/IL-12 Imbalance and T Lymphocyte Polarization in HIV Infection (INTESTIPAX)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01942655|
Recruitment Status : Recruiting
First Posted : September 16, 2013
Last Update Posted : February 27, 2018
|Condition or disease||Intervention/treatment||Phase|
|HIV Reservoirs||Other: Blood sample and recto-colic biopsies||Not Applicable|
Th17 lymphocytes fight bacterial and fungal intestinal infections. Under combined antiretroviral therapy, even if the plasma viral load is undetectable, hyperactivation can persist, inducing localized replication from reservoirs. In humans, Th17 lymphocyte differentiation and expansion depend on IL-23. The investigators were the first to uncover an imbalance in the respective production of IL-12 and IL-23 in response to Lipopolysaccharide (LPS) in HIV-1 infected patients. IL-23 and its receptor are implicated in the pathogenesis of chronic inflammatory bowel diseases (IBD) like Crohn's disease, where the mucosa is altered by Th17 cells, inducing bacterial product translocation. IBD can be efficiently treated by antibodies directed against Tumor Necrosis Factor-α (TNF-α) or, in current clinical trials, against the p40 chain which is shared by IL-12 and IL-23. Unfortunately, these antibodies inhibit also IL-12. IL-12 is crucial against mycobacteria, which are opportunistic in HIV-infected patients. Antibodies directed against the p19 chain of IL-23 would inhibit Th17 activation more specifically.
The investigators will collect blood and recto-colic biopsies from 15 healthy donors, 15 HIV-infected patients with a viral load higher than 5000 copies/ml and 15 patients with evolutive IBD, to establish a parallel between the two diseases.
The objectives of this project are to study if there is a correlation between the IL12/IL-23 imbalance and bacterial product translocation, and to investigate the polarization, infection or depletion of intestinal Th17 ex vivo. Investigators will test the effect of neutralizing anti-IL23 antibodies directed against p40, or less classically, anti- IL-23 p19.
If these correlations are validated, the investigators will propose anti-IL-23 neutralizing treatment to allow Th17 and intestinal integrity to come back into balance, and therefore to break the vicious cycle of immune system hyperactivation drawn by bacterial translocation.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||45 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||ANRS RF002 Intestipax : Interleukin-23 (IL-23)/Interleukin-12 (IL-12) Imbalance and T Lymphocyte Polarization in HIV Infection|
|Actual Study Start Date :||June 1, 2014|
|Estimated Primary Completion Date :||July 2018|
|Estimated Study Completion Date :||July 2019|
Experimental: Patients with recto-colic biopsies prescribed
|Other: Blood sample and recto-colic biopsies|
- Multiple measures: IL-17 and IL-23 producing cells in blood, and IL-17 and IL-23 coding mRNA in intestinal biopsies. [ Time Frame: 25 months ]
- Multiple measures : number of cells producing IL-23 and Th17 cells in intestinal biopsies [ Time Frame: 25 months ]
- Multiple measures : HIV viral load levels in blood and intestinal biopsies [ Time Frame: 25 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01942655
|Contact: Odile Launay, Pr||01 58 41 28 email@example.com|
|Contact: Corinne Desaint||01 58 41 28 firstname.lastname@example.org|
|Centre d'Investigation Clinique BT505, Hôpital Cochin||Recruiting|
|Paris, France, 75014|
|Contact: Odile Launay, Pr 01 58 41 28 60 email@example.com|
|Principal Investigator: Odile Launay, Pr|